Friday, June 20th, 2025
Stock Profile: AVTE

Aerovate Therapeutics, Inc. (AVTE)

Market: NASD | Currency: USD

Address: 930 Winter Street

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.




📈 Aerovate Therapeutics, Inc. Historical Chart






📊 Statistics





💰 Dividend History


Year Annual Yield (%) Total Amount Current Yield (%) Ex Date Pay Date Particulars
2025 - $0.028571 - 2025-04-29 - Stock split
$2.400000 - 2025-04-25 - Dividend payout
Total Amount for 2025: $2.428571


📅 Earnings & EPS History for Aerovate Therapeutics, Inc.


DateReported EPS
2026-03-25 (estimated upcoming)-
2025-11-10 (estimated upcoming)-
2025-11-09 (estimated upcoming)-
2025-08-11 (estimated upcoming)-
2025-08-10 (estimated upcoming)-
2025-05-12-
2025-05-11-
2025-03-27-
2025-03-25-0.19
2025-03-23-
2024-11-12-0.56
2024-08-12-0.86
2024-08-11-0.86
2024-05-13-0.83
2024-05-12-0.83
2024-03-25-0.74
2024-03-24-0.74
2023-11-13-0.71
2023-11-12-0.71
2023-08-14-0.76
2023-08-13-0.76
2023-05-15-0.67
2023-05-14-0.67
2023-03-29-0.61
2023-03-28-0.61
2022-11-14-0.56
2022-11-13-0.56
2022-08-15-0.49
2022-08-14-0.49
2022-05-16-0.45
2022-05-15-0.45
2022-03-30-0.35
2022-03-29-0.35
2021-11-15-0.26
2021-11-14-0.26
2021-08-16-23.8
2021-08-15-23.8
2021-06-30-
2021-06-29-




📰 Related News & Research


No related articles found for "aerovate therapeutics".